title: Circulating pro-surfactant protein B as a risk biomarker for lung cancer.
abstract: BACKGROUND
  Our prior studies of lung cancer suggested that a novel biomarker (pro-surfactant protein B or pro-SFTPB) might serve as a predictive marker for this disease. We aimed to determine the potential use of pro-SFTPB for distinguishing lung cancer cases from matched controls as a risk marker.
  
  
  METHODS
  Study subjects were drawn from the longitudinal Physicians' Health Study (PHS). Cases (n = 188) included individuals who were cancer-free at study enrollment but developed lung cancer during follow-up. Controls (n = 337) were subjects who did not develop lung cancer. Cases and controls were matched on date of study enrollment, age at enrollment, and smoking status and amount. Baseline plasma samples drawn at enrollment were analyzed for pro-SFTPB using ELISA to detect differences in protein expression levels for cases and controls.
  
  
  RESULTS
  Pro-SFTPB nondetectable status was significantly associated with lung cancer risk [OR = 5.88; 95% confidence interval (CI) 1.24-27.48]. Among subjects with detectable levels of the protein, increasing plasma concentration of pro-SFTPB was associated with higher lung cancer risk (OR = 1.41 per unit increase in log pro-SFTPB; 95% CI 1.08-1.84).
  
  
  CONCLUSIONS
  These results suggest a nonlinear, J-shaped association between plasma pro-SFTPB levels and lung cancer risk, with both nondetectable and higher levels of the marker being associated with lung cancer.
  
  
  CONCLUSIONS
  These results show promise of a risk marker that could contribute to predicting risk for lung cancer development and to narrowing the high-risk population for low-dose computed tomography screening.
authors.affiliation: Authors' Affiliations: Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Epidemiology, Biostatistics, and Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York; Divisions of Preventive Medicine and Aging, Department of Medicine, Brigham and Women's Hospital; and Boston VA Medical Center, Boston, Massachusetts.
authors.forename: Ayumu
authors.initials: A
authors.lastname: Taguchi
authors.forename: Samir
authors.initials: S
authors.lastname: Hanash
authors.forename: Andrew
authors.initials: A
authors.lastname: Rundle
authors.forename: Ian W
authors.initials: IW
authors.lastname: McKeague
authors.forename: Deliang
authors.initials: D
authors.lastname: Tang
authors.forename: Salima
authors.initials: S
authors.lastname: Darakjy
authors.forename: J Michael
authors.initials: JM
authors.lastname: Gaziano
authors.forename: Howard D
authors.initials: HD
authors.lastname: Sesso
authors.forename: Frederica
authors.initials: F
authors.lastname: Perera
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011961:Receptors, Fc / Q000097:blood*; D012307:Risk Factors; D014815:Vitamins / Q000008:administration & dosage; D019207:beta Carotene / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; C045281:IgA receptor; D011961:Receptors, Fc; D014815:Vitamins; D019207:beta Carotene
references.citation: JAMA. 2009 Jan 7;301(1):52-62
references.pmid: 19066368
references.citation: Am J Respir Crit Care Med. 1999 Dec;160(6):1843-50
references.pmid: 10588595
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: J Natl Cancer Inst. 2011 Jul 20;103(14):1112-22
references.pmid: 21685357
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Am J Respir Cell Mol Biol. 2003 Mar;28(3):373-8
references.pmid: 12594064
references.citation: Eur Respir J. 2002 Nov;20(5):1152-61
references.pmid: 12449168
references.citation: Am J Respir Cell Mol Biol. 2000 Oct;23(4):466-74
references.pmid: 11017911
references.citation: Nat Rev Cancer. 2007 Oct;7(10):778-90
references.pmid: 17882278
references.citation: Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L755-65
references.pmid: 12225952
references.citation: N Engl J Med. 2011 Aug 4;365(5):395-409
references.pmid: 21714641
references.citation: Cancer Cell. 2011 Sep 13;20(3):289-99
references.pmid: 21907921
references.citation: JAMA. 2012 Jun 13;307(22):2418-29
references.pmid: 22610500
references.citation: J Histochem Cytochem. 1996 Jul;44(7):673-8
references.pmid: 8675988
references.citation: Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2136-43
references.pmid: 21817103
references.citation: N Engl J Med. 1996 May 2;334(18):1145-9
references.pmid: 8602179
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1899-907
references.pmid: 16103435
references.citation: N Engl J Med. 1989 Jul 20;321(3):129-35
references.pmid: 2664509
references.citation: JAMA. 2008 Nov 12;300(18):2123-33
references.pmid: 18997197
references.citation: CA Cancer J Clin. 2013 Mar-Apr;63(2):107-17
references.pmid: 23315954
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2262-72
references.pmid: 21828236
references.citation: Am J Ind Med. 2005 Dec;48(6):419-31
references.pmid: 16299703